Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: a double-blind, placebo-controlled clinical trial

Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. This is a randomized, do...

Full description

Saved in:
Bibliographic Details
Published inClinical, cosmetic and investigational dermatology Vol. 9; pp. 325 - 332
Main Authors Juturu, Vijaya, Bowman, James, Deshpande, Jayant
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2016
Taylor & Francis Ltd
Dove Medical Press
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: -zeaxanthin and ( )-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter . The individual typological angle was calculated. Subjective assessments were also recorded. Overall skin tone was significantly improved in the L/Zi group compared to placebo ( <0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle. L/Zi supplementation lightens and improves skin conditions.
AbstractList Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. Subjects and methods: This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18–45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II–IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded. Results: Overall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle. Conclusion: L/Zi supplementation lightens and improves skin conditions.
Vijaya Juturu,1 James P Bowman,2 Jayant Deshpande1 1Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ, 2James P Bowman & Associates LLC, Loveland, OH, USA Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants.Subjects and methods: This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10mg lutein (L) and 2mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded.Results: Overall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle.Conclusion: L/Zi supplementation lightens and improves skin conditions. Keywords: lutein, zeaxanthin isomers, skin lightening, minimal erythemal dose, individual typological angle, overall skin tone
Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: -zeaxanthin and ( )-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter . The individual typological angle was calculated. Subjective assessments were also recorded. Overall skin tone was significantly improved in the L/Zi group compared to placebo ( <0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle. L/Zi supplementation lightens and improves skin conditions.
Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants.PURPOSECarotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants.This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded.SUBJECTS AND METHODSThis is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded.Overall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle.RESULTSOverall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle.L/Zi supplementation lightens and improves skin conditions.CONCLUSIONL/Zi supplementation lightens and improves skin conditions.
Audience Academic
Author Juturu, Vijaya
Bowman, James
Deshpande, Jayant
AuthorAffiliation 1 Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ
2 James P Bowman & Associates LLC, Loveland, OH, USA
AuthorAffiliation_xml – name: 1 Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ
– name: 2 James P Bowman & Associates LLC, Loveland, OH, USA
Author_xml – sequence: 1
  givenname: Vijaya
  surname: Juturu
  fullname: Juturu, Vijaya
– sequence: 2
  givenname: James
  surname: Bowman
  fullname: Bowman, James
– sequence: 3
  givenname: Jayant
  surname: Deshpande
  fullname: Deshpande, Jayant
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27785083$$D View this record in MEDLINE/PubMed
BookMark eNptkltvFCEUxyemxtbaN58NiYnxoVO5DjM-mDTrbZMmfVCfCQPMDpWBLTDr5fv4PWW7W9M2wgMczv_8wrk8rQ588KaqniN4hhHlbxaL5fuzLwgxhrpH1RFCvK05ROzgzv2wOknpCpZFOsZJ-6Q6xJy3DLbkqPpzuTFROgfSd-tBLnQgvb6xamdXYzbe-lVtp3UMm3IDZhiMygn8sHkEoYSCNK_XzkzGZ5lt8CAMwM3ZFNyW9NvIn9LnsZg2hcnE9BZIoMPcO1P3znp9CtZOKtOHWgWfY3DOaKCKx6pCz9FK96x6PEiXzMn-PK6-ffzwdfG5vrj8tFycX9SKwS7XUms19BL1irOeNlpzrBHuSWsIastumo6QnhDFYUnfwF4yCqHRLSJ40Lghx9Vyx9VBXol1tJOMv0SQVtw8hLgSMmarnBEQDVRTjgiFlHZ4kB2ThDDZ0UZSrGhhvdux1nM_Ga1KfUq17kHve7wdxSpsBIMNYR0qgNd7QAzXs0lZTDYp45z0JsxJoJYwRjCnbZG-fCC9CnP0pVQCY8waTrt2q3q1U61kSWA00uUxhdKr0rUkzhuIO8wZYkX44u7X__35dmyKAO8EKoaUohmEsrvul0ysEwiK7XiK7XiK_XiWoNMHQbfc_8r_Anvn55U
CitedBy_id crossref_primary_10_61873_YAOK3799
crossref_primary_10_1111_jocd_12747
crossref_primary_10_1007_s10811_024_03372_1
crossref_primary_10_1016_j_tifs_2021_10_017
crossref_primary_10_1111_jfpp_15260
crossref_primary_10_1016_j_fct_2021_112328
crossref_primary_10_3390_ijms25031431
crossref_primary_10_1016_j_plaphy_2022_09_034
crossref_primary_10_3390_ijms242015199
crossref_primary_10_1093_nutrit_nuz096
crossref_primary_10_3390_md22030131
crossref_primary_10_1016_j_chemosphere_2021_132932
crossref_primary_10_1016_j_tifs_2019_11_015
crossref_primary_10_3390_pharmaceutics14102160
crossref_primary_10_3892_br_2022_1545
crossref_primary_10_1007_s13671_020_00306_1
crossref_primary_10_4236_jcdsa_2020_104020
crossref_primary_10_1007_s44187_025_00287_9
crossref_primary_10_3892_br_2024_1742
crossref_primary_10_1016_j_jaad_2020_03_115
crossref_primary_10_3746_pnf_2021_26_4_425
crossref_primary_10_1007_s12634_018_5628_y
crossref_primary_10_1007_s11274_023_03747_5
crossref_primary_10_3390_nu14061248
crossref_primary_10_3390_antiox8080259
crossref_primary_10_1016_j_psj_2021_101054
crossref_primary_10_1016_j_jff_2020_104265
crossref_primary_10_1007_s13659_022_00363_y
crossref_primary_10_3390_cosmetics8030070
crossref_primary_10_1016_j_aqrep_2022_101388
crossref_primary_10_1007_s13555_018_0221_x
crossref_primary_10_1016_j_ijbiomac_2024_133839
crossref_primary_10_3389_fvets_2022_906853
crossref_primary_10_3390_molecules27165334
crossref_primary_10_1111_azo_12488
crossref_primary_10_1111_jocd_13854
crossref_primary_10_1007_s13555_019_00345_y
crossref_primary_10_1111_jocd_70017
crossref_primary_10_3390_foods12132516
crossref_primary_10_1002_jvc2_385
crossref_primary_10_7759_cureus_40892
crossref_primary_10_1016_j_nutres_2021_04_007
crossref_primary_10_3390_jcm12237488
crossref_primary_10_1111_php_13525
crossref_primary_10_3390_antiox10091448
crossref_primary_10_1007_s15011_018_2051_7
crossref_primary_10_3390_nu13010203
crossref_primary_10_1111_jocd_14137
crossref_primary_10_1155_2022_7881717
crossref_primary_10_3390_antiox10101511
crossref_primary_10_1111_phpp_12423
crossref_primary_10_1016_j_clindermatol_2021_05_007
crossref_primary_10_3390_cosmetics10050143
crossref_primary_10_3390_cosmetics10050142
crossref_primary_10_3390_scipharm88020027
crossref_primary_10_1016_j_phymed_2024_155508
crossref_primary_10_3390_life13051120
ContentType Journal Article
Copyright COPYRIGHT 2016 Dove Medical Press Limited
2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2016 Juturu et al. This work is published and licensed by Dove Medical Press Limited 2016
Copyright_xml – notice: COPYRIGHT 2016 Dove Medical Press Limited
– notice: 2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2016 Juturu et al. This work is published and licensed by Dove Medical Press Limited 2016
DBID AAYXX
CITATION
NPM
3V.
7RV
7XB
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
KB0
M2O
MBDVC
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.2147/CCID.S115519
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Nursing & Allied Health Database (NC LIVE)
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
Nursing & Allied Health Database (Alumni Edition)
ProQuest Research Library (NC LIVE)
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
Health Research Premium Collection
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1178-7015
EndPage 332
ExternalDocumentID oai_doaj_org_article_01f4d4713404492fa95a335a946a42c4
PMC5063591
A602927515
27785083
10_2147_CCID_S115519
Genre Journal Article
GroupedDBID ---
0YH
29B
2WC
53G
5VS
7RV
8FI
8FJ
8G5
AAYXX
ABUWG
ADBBV
ADRAZ
AFKRA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BKEYQ
BPHCQ
BVXVI
C1A
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
FYUFA
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HYE
IAO
IHR
IHW
IPNFZ
ITC
KQ8
M2O
M48
M~E
NAPCQ
O5R
O5S
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RIG
RPM
TDBHL
TR2
TUS
UKHRP
VDV
NPM
3V.
7XB
8FK
MBDVC
PKEHL
PPXIY
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c509t-addcfba1bc75b46dd72d12b38e31818166933b33c70850e0ba5400ed8132fd263
IEDL.DBID M48
ISSN 1178-7015
IngestDate Wed Aug 27 01:19:02 EDT 2025
Thu Aug 21 18:04:37 EDT 2025
Thu Jul 10 18:48:46 EDT 2025
Fri Jul 25 08:37:57 EDT 2025
Thu May 22 21:18:41 EDT 2025
Thu Jan 02 22:21:29 EST 2025
Thu Apr 24 23:05:08 EDT 2025
Tue Jul 01 01:55:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords zeaxanthin isomers
overall skin tone
individual typological angle
minimal erythemal dose
lutein
skin lightening
Language English
License http://creativecommons.org/licenses/by-nc/3.0
The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c509t-addcfba1bc75b46dd72d12b38e31818166933b33c70850e0ba5400ed8132fd263
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/CCID.S115519
PMID 27785083
PQID 2225674988
PQPubID 3933178
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_01f4d4713404492fa95a335a946a42c4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5063591
proquest_miscellaneous_1835532748
proquest_journals_2225674988
gale_healthsolutions_A602927515
pubmed_primary_27785083
crossref_citationtrail_10_2147_CCID_S115519
crossref_primary_10_2147_CCID_S115519
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-01-01
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-01
  day: 01
PublicationDecade 2010
PublicationPlace New Zealand
PublicationPlace_xml – name: New Zealand
– name: Auckland
PublicationTitle Clinical, cosmetic and investigational dermatology
PublicationTitleAlternate Clin Cosmet Investig Dermatol
PublicationYear 2016
Publisher Dove Medical Press Limited
Taylor & Francis Ltd
Dove Medical Press
Publisher_xml – name: Dove Medical Press Limited
– name: Taylor & Francis Ltd
– name: Dove Medical Press
References 12880433 - J Invest Dermatol. 2003 Aug;121(2):399-405
23644932 - JAMA. 2013 May 15;309(19):2005-15
25741404 - Oxid Med Cell Longev. 2015;2015:579675
15949675 - Biochim Biophys Acta. 2005 May 30;1740(2):101-7
19122479 - Skin Pharmacol Physiol. 2009;22(1):31-44
17717424 - Skin Pharmacol Physiol. 2007;20(6):283-91
16556283 - J Dermatol. 2006 Feb;33(2):132-4
19168000 - Clin Dermatol. 2009 Mar-Apr;27(2):195-201
5696561 - Calif Med. 1968 Oct;109(4):319-20
7603884 - Nutr Cancer. 1995;23(3):233-46
8554331 - Arch Biochem Biophys. 1995 Dec 20;324(2):385-90
9478000 - Invest Ophthalmol Vis Sci. 1998 Feb;39(2):397-406
9651820 - J Dermatol Sci. 1998 Mar;16(3):226-30
16978905 - Int J Biochem Cell Biol. 2007;39(1):44-84
12239422 - Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):291-6
23605606 - Acta Med Iran. 2013 Apr 06;51(3):195-8
16400064 - Am J Clin Nutr. 2006 Jan;83(1):163-9
9828775 - Br J Ophthalmol. 1998 Aug;82(8):907-10
14585305 - Mol Aspects Med. 2003 Dec;24(6):345-51
17446716 - Skin Pharmacol Physiol. 2007;20(4):199-210
10609870 - Biofactors. 1999;10(2-3):105-13
18669545 - Br J Ophthalmol. 2008 Sep;92(9):1163-8
8127329 - N Engl J Med. 1994 Apr 14;330(15):1029-35
15009738 - J Invest Dermatol. 2004 Feb;122(2):510-7
24742502 - Ageing Res Rev. 2014 Jul;16:1-11
14513828 - Br J Nutr. 2003 Sep;90(3):487-502
12747216 - Int J Vitam Nutr Res. 2003 Mar;73(2):95-100
8602180 - N Engl J Med. 1996 May 2;334(18):1150-5
12514275 - J Nutr. 2003 Jan;133(1):98-101
15570017 - J Nutr. 2004 Dec;134(12):3225-32
18227626 - Ann Nutr Metab. 2007;51(6):571-3
17070769 - Biochim Biophys Acta. 2007 Jan;1768(1):167-74
18044138 - Clin Interv Aging. 2007;2(2):219-36
11444419 - J Am Coll Nutr. 2001 Jun;20(3):232-8
15189118 - Annu Rev Nutr. 2004;24:173-200
9675037 - Arch Biochem Biophys. 1998 Jul 15;355(2):271-4
17173569 - J Cosmet Dermatol. 2006 Mar;5(1):30-8
15068825 - Toxicol Lett. 2004 Apr 15;150(1):57-83
9886572 - Carcinogenesis. 1998 Dec;19(12):2159-62
17656988 - Indian J Dermatol Venereol Leprol. 2002 Nov-Dec;68(6):320-2
References_xml – reference: 15189118 - Annu Rev Nutr. 2004;24:173-200
– reference: 15570017 - J Nutr. 2004 Dec;134(12):3225-32
– reference: 16978905 - Int J Biochem Cell Biol. 2007;39(1):44-84
– reference: 12747216 - Int J Vitam Nutr Res. 2003 Mar;73(2):95-100
– reference: 9478000 - Invest Ophthalmol Vis Sci. 1998 Feb;39(2):397-406
– reference: 7603884 - Nutr Cancer. 1995;23(3):233-46
– reference: 9651820 - J Dermatol Sci. 1998 Mar;16(3):226-30
– reference: 16556283 - J Dermatol. 2006 Feb;33(2):132-4
– reference: 8554331 - Arch Biochem Biophys. 1995 Dec 20;324(2):385-90
– reference: 14513828 - Br J Nutr. 2003 Sep;90(3):487-502
– reference: 8602180 - N Engl J Med. 1996 May 2;334(18):1150-5
– reference: 9828775 - Br J Ophthalmol. 1998 Aug;82(8):907-10
– reference: 17446716 - Skin Pharmacol Physiol. 2007;20(4):199-210
– reference: 23644932 - JAMA. 2013 May 15;309(19):2005-15
– reference: 17717424 - Skin Pharmacol Physiol. 2007;20(6):283-91
– reference: 17173569 - J Cosmet Dermatol. 2006 Mar;5(1):30-8
– reference: 12880433 - J Invest Dermatol. 2003 Aug;121(2):399-405
– reference: 12239422 - Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):291-6
– reference: 15068825 - Toxicol Lett. 2004 Apr 15;150(1):57-83
– reference: 15949675 - Biochim Biophys Acta. 2005 May 30;1740(2):101-7
– reference: 19168000 - Clin Dermatol. 2009 Mar-Apr;27(2):195-201
– reference: 25741404 - Oxid Med Cell Longev. 2015;2015:579675
– reference: 11444419 - J Am Coll Nutr. 2001 Jun;20(3):232-8
– reference: 18669545 - Br J Ophthalmol. 2008 Sep;92(9):1163-8
– reference: 12514275 - J Nutr. 2003 Jan;133(1):98-101
– reference: 9675037 - Arch Biochem Biophys. 1998 Jul 15;355(2):271-4
– reference: 16400064 - Am J Clin Nutr. 2006 Jan;83(1):163-9
– reference: 10609870 - Biofactors. 1999;10(2-3):105-13
– reference: 23605606 - Acta Med Iran. 2013 Apr 06;51(3):195-8
– reference: 24742502 - Ageing Res Rev. 2014 Jul;16:1-11
– reference: 18227626 - Ann Nutr Metab. 2007;51(6):571-3
– reference: 18044138 - Clin Interv Aging. 2007;2(2):219-36
– reference: 19122479 - Skin Pharmacol Physiol. 2009;22(1):31-44
– reference: 5696561 - Calif Med. 1968 Oct;109(4):319-20
– reference: 17656988 - Indian J Dermatol Venereol Leprol. 2002 Nov-Dec;68(6):320-2
– reference: 14585305 - Mol Aspects Med. 2003 Dec;24(6):345-51
– reference: 17070769 - Biochim Biophys Acta. 2007 Jan;1768(1):167-74
– reference: 8127329 - N Engl J Med. 1994 Apr 14;330(15):1029-35
– reference: 9886572 - Carcinogenesis. 1998 Dec;19(12):2159-62
– reference: 15009738 - J Invest Dermatol. 2004 Feb;122(2):510-7
SSID ssj0000395738
Score 2.3053322
Snippet Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources....
Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy...
Vijaya Juturu,1 James P Bowman,2 Jayant Deshpande1 1Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ, 2James...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 325
SubjectTerms Acne
Antioxidants
Antioxidants (Nutrients)
Cancer
Carotenoids
Clinical trials
Diet
Disease
Double-blind studies
Energy resources
Family medical history
Fibroblasts
Free radicals
Fruits
Individual Typological Angle (ITA)
Inflammation
Lipids
Lutein
Minimal Erythemal Dose (MED)
Nutrition research
Original Research
Overall Skin Tone
Oxidative stress
Skin
Skin care
Skin Lightening
Ultraviolet radiation
Vegetables
Zeaxanthin Isomers (L/Zi)
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yB_EifltdNYKeNG7bJE3jbX26rMLqxYW9haRJ2YelFfueiP-P_6czaV55RcSLx7ahNJ1fJr_5yAwhzyrbitbZgimf10xUZcNcaDlTVoYKEBVEixHds4_V6bn4cCEv9lp9YU7YVB54-nFHedEKL_DEYy6ELlurpeVcWi0qK8omVgKFPW_PmIo6GMNPsY11UYCZpGDTm7LesS3P0Wr1_u0rWMfAFvRiP4pl-_9Uznu70zJzcm8rOrlBricOSY-nb79JroT-Frl6lqLkt8mvT9_R09TR8cu6p1htm9rexyvWoTEe0BnC1jt_Ak1JHRSdshSP7NMRm31OieUoOTq0FCAa4HX4pp_B_gCJXMLlehzQ8_2aWuqHresCc0Bc_Usak73cwFIufBc83Z3CpLFVyB1yfvLu8-qUpXYMrAFWsWGgCRsUq2uUdKLyXpW-KB2v0Y1aYPxRc-44bxSWwQu5s8AG8-BrMHhbX1b8LjnoYcr3CW0AIcFLrS0axby1bQ3EMrg8OC99sBl5sROKaVKtcmyZ0RmwWVCEBkVokggz8nwe_XWq0fGXcW9QvvMYrKwdbwDeTMKb-RfeMvIE0WGmY6qzfjDHVV7qUgE9zMjhDjgmKYTRoFldKaHrOiNP58ewlDE-Y_swbEcD2lVKDn8ExtybcDZ_a6lUjZX7M6IWCFxMZvmkX1_GcuESWKjUxYP_MfuH5BowxuSDOiQHm2_b8AhY2cY9jgvwNyDaNX4
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiHdDCxgJTmCaxHYeXFC7tCpILQhRqTfLjm26IkraZhch_g__k5nECV0hODqxoiQzHn_zzXiGkOeZ9sIbnbDcxgUTWVox4zxnuZYuA41ywmNE9-g4OzwRH07laSDcupBWOdrE3lDbtkKOfAf9kiwXZVG8Pb9g2DUKo6uhhcZ1sgEmuChmZGNv__jT54lliTEMxYsh4x1b8uzM5-_fvYY1DEihXNuL-pL9fxvmKzvTetbklW3o4Da5FfAj3R0Efodcc81dcuMoRMjvkV8fvyPLVNPu26KhWGmb6sb2I1ajI-6QCGGLkUugIaGDIiFL8bg-7bDR55BUjlKjraegng4eh0_66fQPkMYZDBddi6z3G6qpbVemdswAaLWvaJ_oZVoW8uBrZ-l4ApP2bULuk5OD_S_zQxZaMbAKEMWSgRWsUKSmyqURmbV5apPU8AIp1ARjjyXnhvMqxxJ4LjYakGDsbAHOrrdpxh-QWQOfvEloBdrhrCxLjQ4x99oXACqdiZ2x0jodkZejUFQV6pRju4xagb-CIlQoQhVEGJEX0-zzoT7HP-btoXynOVhVu7_QXn5VYZGqOPHCCjxdGwtRpl6XUnMudSkyLdJKROQpaocajqhOtkHtZnFapjlAw4hsj4qjgjHo1B_Vjciz6TYsY4zN6Ma1q06BZZWSwx-BOQ8HPZveNc3zAqv2RyRf08C1j1m_0yzO-lLhEhCoLJNH_3-tLXITcGBglrbJbHm5co8Bay3Nk7CgfgOI7y4c
  priority: 102
  providerName: ProQuest
Title Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: a double-blind, placebo-controlled clinical trial
URI https://www.ncbi.nlm.nih.gov/pubmed/27785083
https://www.proquest.com/docview/2225674988
https://www.proquest.com/docview/1835532748
https://pubmed.ncbi.nlm.nih.gov/PMC5063591
https://doaj.org/article/01f4d4713404492fa95a335a946a42c4
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bi9QwFA57AfFFvFtdxwj6pFl7SZpWENkddxmFWUUcWJ9C0qTuYGl1OiOr_8f_6TltOuywio9tQ2h7bt-55BxCnqS65KXREZM2zBhP44IZVyZMauFS4CjHS8zoTk_SyYy_OxWnW2SYNup_YPtX1w7nSc0W1f7595-vQeBfYRlzxOWL8fjtm30QSzD--TbZBZskcZbB1AP9TidjOqobax1F4DZJMIJ9FfylDTbsU9fG_7KyvmCtNispL5im4-vkmseU9KBnghtky9U3yZWpz5rfIr_f_8DIU0Xbr_OaYvdtqmvbXbEKnXOHwRE2H-IL1Bd5UAzSUjzCT1sc_tkXmiMlaVNSYFkH2-FOv5w-BwqdweW8bTAS_pJqapuVqRwzAGTtc9oVf5mG-dr4ylk6nMqk3eiQ22R2fPRpPGF-PAMrAGUsGWjGAslsCikMT62VsY1ik2QYVo0wH5kniUmSQmJbPBcaDegwdDYDB7i0cZrcITs1fPI9QgvgGGdFnmt0kpNSlxkATWdCZ6ywTgfk2UAUVfje5ThCo1LgwyAJFZJQeRIG5Ol69be-Z8c_1h0ifddrsNN2d6NZfFFecFUYldxyPHEbcp7Hpc6FThKhc55qHhc8II-QO1R_bHWtL9RBGsZ5LAEuBmRvYBw18LdCNzuVPM-ygDxePwbRxnyNrl2zahVoWyES-COw5m7PZ-t3jaXMsJN_QOQGB258zOaTen7WtQ8XgEpFHt3_74s_IFcBHvqA0x7ZWS5W7iFAsKUZke3w82REdg-PTj58HHWBjFEncX8AJvU1Pg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKKgEXxJuFQo1ET-B2Y3tfSAi1aauENgGhVurN2GsvjYh2Szfh9X-48huZ2ReNENx63KxleTPfvMczhDwLdSYzo_sssn7MZMhTZlwmWKQDFwKinMwwozuehMNj-eYkOFkhv9q7MFhW2crESlDbIsUY-Rb6JWEkkzh-ffaZ4dQozK62IzRqWBy471_BZStfjXaBvhuc7-8dDYasmSrAUlCOcwYMneLpTBoFRobWRtz2uRExRgP7mEYDH98IkUbYzc35RoNR4zsbg9-WWR4K2PcKWZUi9HmPrO7sTd6976I6Pqa9RFxX2OMIoK3BYLS7CTIDLJNkSfdVIwL-VgQXNOFyleYFtbd_k9xo7FW6XQPsFllx-W1yddxk5O-Qn2-_YFRrRstP05xiZ2-qc1s9sRk6_g4DL2zaxi5oU0BCMQBMsT0ALXGwaF3EjiihRUaBHRxshzv9cPobUP8UHqdlgVH2l1RTWyzMzDEDRrJ9QavCMlOwpu5-5ixtb3zSaizJXXJ8KUS6R3o5fPIDQlNAo7NBkmh0wEWmsxiMWGd8Z2xgnfbI85YoKm36ouN4jpkC_whJqJCEqiGhRza61Wd1P5B_rNtB-nZrsIt39UNx_lE1QkH5_Uxaibd5fSkTnukk0EIEOpGhljyVHllHdKj6Smwni9Q2QC_hEZiiHllrgaMa4VOqP6zikafdaxAbmAvSuSsWpQJJHgQC_hFYc7_GWXdWHkUxTgnwSLSEwKWPWX6TT0-r1uQBWLxB0n_4_2Otk2vDo_GhOhxNDh6R62CDNlGtNdKbny_cY7Dz5uZJw1yUfLhsfv4NSbNqhw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ028IO5kDGYk9gRmaWLngoTQ1q5aGSsTYtLejB07rFqVjKXl9n_4E_w6zkmcsArB2x7TWJbT85378TmEPI1UznOt-iw2fsJ4FGRM2zxksRI2AkRZnmNG93AS7R_zNyfiZIX8au_CYFllKxNrQW3KDGPk2-iXRDFPwWHLXVnE0XD0-vwzwwlSmGltx2k0EDmw37-C-1a9Gg-B1ltBMNr7MNhnbsIAy0BRzhkwd4Yn1VksNI-MiQPTD3SYYGSwjyk18Pd1GGYxdnazvlZg4PjWJODD5SaIQtj3GlmN0SvqkdXdvcnR-y7C42MKLEyaanscB7Q9GIyHL0B-gJWSLunBelzA30rhklZcrti8pAJHN8kNZ7vSnQZst8iKLW6TtUOXnb9Dfr77ghGuGa3OpgXFLt9UFaZ-YjMMAlgMwrBpG8egrpiEYjCYYqsAWuGQ0aagHRFDy5wCa1jYDnf6YdU3QMIpPE6rEiPuL6miplzomWUaDGbznNZFZrpkrgZ_Zg1tb3_SekTJXXJ8JUS6R3oFfPIDQjNApjUiTRU642Gu8gQMWqt9q40wVnnkWUsUmbke6TiqYybBV0ISSiShdCT0yFa3-rzpDfKPdbtI324NdvSufygvPkknIKTfz7nheLPX5zwNcpUKFYZCpTxSPMi4RzYRHbK5HtvJJbkT-UEaxGCWemSjBY50gqiSf9jGI0-61yBCMC-kClsuKglSXYgQ_hFYc7_BWXfWII4TnBjgkXgJgUsfs_ymmJ7WbcoFWL8i7a___1ibZA34WL4dTw4ekutgjroA1wbpzS8W9hGYfHP92PEWJR-vmp1_A_xwbrw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overall+skin+tone+and+skin-lightening-improving+effects+with+oral+supplementation+of+lutein+and+zeaxanthin+isomers%3A+a+double-blind%2C+placebo-controlled+clinical+trial&rft.jtitle=Clinical%2C+cosmetic+and+investigational+dermatology&rft.au=Juturu%2C+Vijaya&rft.au=Bowman%2C+James+P&rft.au=Deshpande%2C+Jayant&rft.date=2016-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-7015&rft.eissn=1178-7015&rft.volume=9&rft.spage=325&rft_id=info:doi/10.2147%2FCCID.S115519&rft.externalDBID=n%2Fa&rft.externalDocID=A602927515
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7015&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7015&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7015&client=summon